We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
+9.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
-$325M
Cap. Flow
-$480M
Cap. Flow %
-19.19%
Top 10 Hldgs %
43.13%
Holding
114
New
31
Increased
17
Reduced
20
Closed
42

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$104M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$96.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$96.1M
4
TMO icon
Thermo Fisher Scientific
TMO
+$86.3M
5
NTRA icon
Natera
NTRA
+$80.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$115M
2
INCY icon
Incyte
INCY
+$95.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.2M
4
ABBV icon
AbbVie
ABBV
+$78.9M
5
IQV icon
IQVIA
IQV
+$77.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.3%
2 Consumer Discretionary 4.43%
3 Real Estate 2.56%
4 Financials 1.86%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OHPA
51
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
$5.29M 0.21%
+547,598
New +$5.38M
EQRX
52
DELISTED
EQRx, Inc. Common Stock
EQRX
$5.16M 0.21%
+500,000
New +$5.12M
NVAX icon
53
PUT
Novavax
NVAX
$1.27B
$4.99M 0.2%
+23,500
New +$4.31M
ABGI
54
DELISTED
ABG Acquisition Corp. I
ABGI
$3.23M 0.13%
329,400
-20,600
-6% -$205K
LKFT
55
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$2.83M 0.11%
41,080
+6,820
+20% +$520K
OMEG
56
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$2.7M 0.11%
271,038
-103,962
-28% -$1.03M
SRSAU
57
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$2.69M 0.11%
262,150
– –
CYT
58
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$2.57M 0.1%
+120,000
New +$2.25M
EUCRU
59
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.39M 0.1%
234,180
-100,000
-30% -$1M
DAWN
60
DELISTED
Day One Biopharmaceuticals
DAWN
$2.36M 0.09%
+103,717
New +$2.16M
GLUE icon
61
Monte Rosa Therapeutics
GLUE
$1.32B
$2.27M 0.09%
+100,000
New +$2.04M
MRUS
62
DELISTED
Merus
MRUS
$2.03M 0.08%
96,438
+35,948
+59% +$795K
JNCE
63
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.82M 0.07%
268,295
+65,710
+32% +$546K
JYAC
64
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.4M 0.06%
140,680
– –
ATAI icon
65
AtaiBeckley Inc
ATAI
$2.67B
$1.39M 0.06%
+75,000
New +$1.39M
ELEV
66
DELISTED
Elevation Oncology
ELEV
$1.36M 0.05%
+100,000
New +$1.24M
BHVN
67
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.07M 0.04%
+11,000
New +$893K
LGV.WS
68
DELISTED
Longview Acquisition Corp. II Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
LGV.WS
$585K 0.02%
+427,178
New +$536K
MREO
69
Mereo BioPharma
MREO
$48.4M
$473K 0.02%
149,170
– –
EQRXW
70
DELISTED
EQRx, Inc. Warrant
EQRXW
$258K 0.01%
+99,998
New +$266K
OHPAW
71
DELISTED
Orion Acquisition Corp. Warrant
OHPAW
$131K 0.01%
+137,305
New +$123K
MSACW
72
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$83K ﹤0.01%
+82,663
New +$65.5K
ABBV icon
73
AbbVie
ABBV
$435B
– –
-729,420
Closed -$78.9M
ACAD icon
74
Acadia Pharmaceuticals
ACAD
$4.93B
– –
-900,490
Closed -$23.2M
AGIO icon
75
Agios Pharmaceuticals
AGIO
$1.89B
– –
-1,532,960
Closed -$79.2M
1 2
3
4 5

Similar funds

IA
Integrity Advisory Overland Park, Kansas $109M AUM 15.71% 1-Year Est. Return
EPC
Emerson Point Capital Larchmont, New York $108M AUM 19.03% 1-Year Est. Return
TCMV
Technology Crossover Management VII Menlo Park, California $107M AUM 51.05% 1-Year Est. Return
SI
Salesforce Inc San Francisco, California $114M AUM 53.18% 1-Year Est. Return
HCWM
Harrison & Co Wealth Management Roanoke, Virginia $103M AUM 9.82% 1-Year Est. Return
PC
Phoenician Capital New York $117M AUM 9.46% 1-Year Est. Return
RF
Resolute Financial Newburyport, Massachusetts $118M AUM 11.75% 1-Year Est. Return
AWM
Align Wealth Management Oklahoma City, Oklahoma $118M AUM

HealthCor Management's Q2 2021 Portfolio in Review

As of Q2 2021, HealthCor Management held 114 positions worth $2.5B, down 11% from $2.83B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

HealthCor Management withdrew a net $480M in Q2 2021, closing 42 positions and reducing 20 holdings. Its most notable exit was Incyte, an estimated $95.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Real Estate.

Against the trend, HealthCor Management opened a new position in CVS Health worth $106M.

  • HealthCor Management's largest Q2 2021 buy was CVS Health: 1,267,330 shares worth $106M.
  • HealthCor Management added most to Biogen in Q2 2021, an estimated $78.4M increase.
  • HealthCor Management's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $115M.
  • HealthCor Management fully exited Incyte in Q2 2021, selling an estimated $95.4M.
  • HealthCor Management's ten largest holdings make up 43% of its $2.5B portfolio in Q2 2021.
  • HealthCor Management opened 31 new positions and closed 42 in Q2 2021.
  • HealthCor Management's portfolio value fell 11% quarter-over-quarter to $2.5B.

Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.